Mobile website
Archive > Volume 23 Issue 3 > 2016,23(3):408-412. DOI:10.3872/j.issn.1007-385X.2016.03.020 Prev Next
Clinical Research
Efficacy of DC-CIK cell combined with EGFR-TKI in treatment of progressive non-small cell lung cancer patients with EGFR-mutation positive
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate efficacy and safety of DC-CIK cell combined with EGFR-TKI (tyrosine kinase inhibitor), erlotinib or gefitinib, treatment for progressive non-small cell lung cancer (NSCLC) patients with EGFR-mutation positive through a retrospective analysis of the patients. Methods: All of selected 34 patients were pathologically diagnosed as progressive NSCLC with EGFR-mutation positive, and treated with erlotinib (150 mg/d) or gefitinib (250 mg/d). Among them, 17 cases accepted the combined DC-CIK cell treatment. Curative effect and changes of peripheral blood CD3+, CD4+ and CD8+ T cell subsets were compared between the combined treatment and mono-drug groups. Results: In the combined treatment group, 7 patients (41.2%) had achieved PR, 8 patients (47.1%) achieved SD, and 2 patients (11.8%) emerged disease progress. Objective remission rate was 41.2%, and disease control rate 88.2%. Incidence of diarrhea in the combined treatment group, was obviously lower than that in the mono-drug group (P<0.05). Peripheral blood CD3+, CD4+ and CD8+ T cell subsets didn’t show any obvious changes before and after the treatment in the mono-drug group. However, in the combined treatment group after the treatment peripheral blood CD3+ and CD4+ T cell subsets were significantly increased (P<0.05) and peripheral blood CD8+ T cell subset decreased (P<0.05). Conclusion: The treatment of DC-CIK cell combined with erlotinib or gefitinib for progressive NSCLC patients with EGFR mutation positive had good efficacy. T cell immune status of the patients in the combined treatment group was significantly improved and adverse reactions tolerable.
Keywords:
Project Supported:
Projects supported by the Science and Technology Key Programs of Liaoning Province（No. 2013225220）
Clc Number:
